Belgian researchers find a crack in the wall of WHO’s top priority pathogens

SlyB protein acts as a lifebuoy and protects bacteria from dying

Brussels 14 December 2023 - In a breakthrough discovery, scientists from VIB-VUB Center for Structural Biology unraveled the mysteries of SlyB, a tiny but mighty protein found in the outer membrane of certain bacteria. When bacteria face stress, SlyB acts as a crucial guardian to protect the bacterial cell from dying. This discovery not only deepens our understanding of bacterial survival mechanisms but also paves the way for potential applications in antimicrobial research. The findings are published in Nature.

Bacteria on the WHO blacklist

Biologists categorize bacteria into two major groups: Gram-positive bacteria, characterized by a single membrane, and Gram-negative bacteria, distinguished by an inner and outer membrane. It is this second membrane that makes the Gram-negative bacteria extra hard to treat. The outer membrane forms an essential protective layer that shields cells from environmental stresses such as antimicrobial peptides and antibiotics. The World Health Organization (WHO) has a top 10 list of the most worrying pathogens. Unsurprisingly, this list is predominantly populated by Gram-negative bacteria. Scientists have eagerly sought vulnerabilities in these double-layered bacteria and now, a team of Belgian researchers at VIB-VUB Center for Structural Biology has made a breakthrough.

Stress conditions in the membrane

Although forming a protective shield to the bacteria, the outer membrane is not failsafe. When under assault from external stressors, the phospholipids in the outer membrane clutter together like oil spills on the cell surface. This creates weak zones in the shield that risk to burst under the water pressure in the cells, resulting in a blow-out of the cell content and bacterial death through a process called lysis.

Bacterial cells exposed to antimicrobial peptides. Without SlyB, the bacterial outer membrane weakens and the cell content leaks out, resulting in the lysis of the cells. Electron microscopy images show the intact (lower left) and damaged (lower right) membranes of Gram-negative bacteria.

SlyB: the bacterial lifebuoy

Enter SlyB, a protein with a function previously unexplored in science. When cells sense membrane weakening stresses, SlyB comes into play. The protein moves to the phospholipid spills, where it creates ring-shaped nanodisc structures - akin to a lifebuoy. The SlyB nanodiscs encapsulate the proteins in the compromised zones of the outer membrane. This SlyB activity protects the proteins and reinforces the weaker sections of the outer membrane, preventing the excessive loss of essential proteins and ensuring the overall health and survival of the bacteria. Without SlyB the membrane becomes punctured and cells bleed out and lyse. ​

“With this discovery, we have gained a profound new insight into how Gram-negative bacteria protect themselves from membrane destabilizing conditions” says Arne Janssens, PhD student at VIB-VUB Center for Structural Biology.
Schematic representation of the formation of the SlyB nanodisc within phospholipid ‘spills’ (pink) in the outer membrane. SlyB forms a ‘lifebuoy’ around the spills and embedded proteins (green), thus protecting the outer membrane of the bacteria from rupturing.

Future applications

The study not only brings fundamental insights in a novel family of nanodisc-forming proteins, it also provides new tools to fight the bacteria. The Belgian researchers are already progressing to the next steps by using SlyB’s unique properties to their own benefit. The nanodiscs with bacterial membrane proteins are purified and used as vaccination vehicles to stimulate the immune system so it can recognize incoming threats better. The discovery also creates perspectives in the generation of new drugs that prevent Gram-negative bacteria from forming the nanodiscs, rendering them unable to fence off assaults.

“Focusing on these nanodiscs, we aim to turn the bacteria’s protection strategy into its Achilles heel,” says Prof. Han Remaut, Group Leader at VIB-VUB Center for Structural Biology. “By doing so, we discover novel methods to combat Gram-negative bacteria and ultimately shorten the WHO's list of concerning pathogens.”

Publication

https://www.nature.com/articles/s41586-023-06925-5

The study is a collaboration between scientists from Flanders Institute for Biotechnology (VIB), VU Brussel, UGent, UCL Louvain-La-Neuve, and Colorado School of Mines (USA).


Joran Lauwers

Joran Lauwers

Press Contact, VIB

About the VIB-VUB Center for Structural Biology

Proteins are the most important building blocks of all life. They are responsible for the metabolic processes in a cell, they give the cell its shape and enable cooperation between the various cells and tissues in our bodies. Scientists at the VIB-VUB Center for Structural Biology study the basic principles that determine the function and action of a protein in the cell. In this way, we can develop new technologies and bio-based materials.

About VIB

VIB’s core mission is to generate disruptive insights in the molecular underpinning of life and to translate these actively into impactful innovations for patients and society. VIB is an independent research institute where some 1,800 top scientists from Belgium and abroad conduct pioneering basic research. As such, they are pushing the boundaries of what we know about molecular mechanisms and how they rule living organisms such as human beings, animals, plants, and microorganisms. Based on a close partnership with five Flemish universities – Ghent University, KU Leuven, University of Antwerp, Vrije Universiteit Brussel, and Hasselt University – and supported by a solid funding program, VIB unites the expertise of all its collaborators and research groups in a single institute. VIB’s technology transfer activities translate research results into concrete benefits for society such as new diagnostics and therapies and agricultural innovations. These applications are often developed by young start-ups from VIB or through collaborations with other companies. This also leads to additional employment and bridges the gap between scientific research and entrepreneurship. VIB also engages actively in the public debate on biotechnology by developing and disseminating a wide range of science-based information. 

More info can be found on www.vib.be.

 

Share

Latest stories

Website preview
Blocking lipid production in healthy lung cells can reduce lung metastasis
Leuven, 17 March 2026 - Scientists from the VIB–KU Leuven Center for Cancer Biology, in collaboration with the Francis Crick Institute, have discovered how cancer cells can exploit healthy lung cells to support metastatic tumor growth in the lungs. In two complementary studies published in Nature Cell Biology and Cancer Discovery, they show that tumors use lipids produced by lung cells as signals, and that decreasing the lipid production of lung cells can decrease metastasis. The findings point to new therapeutic strategies that target lung cell lipid production, rather than cancer cells themselves, which may also help refine patient selection for ongoing clinical trials targeting this pathway.
press.vib.be
Website preview
Researchers identify major genetic risk factor for rare form of dementia
Antwerp, 12 March 2026 - Researchers at VIB and Antwerp University have identified a major genetic risk factor for a rare form of frontotemporal dementia. The discovery, published today in Nature Genetics, provides a biological entry point for a disease subtype that has been difficult to study. It could not only help to improve diagnosis and patient stratification, but also opens up new avenues toward targeted treatments.
press.vib.be
Website preview
Protealis Announces Regulatory Approval of its First Biological Solution MagNfixTM and Launch of Five New Soybean Varieties
Ghent (Belgium), 11 March 2026 – Protealis, the European specialist in non-GMO legume seeds and seed technologies, today announces several milestones that significantly strengthen its position in a fast-growing European soybean market. The company has obtained European regulatory approval from EFCI1 (EU Fertilising Products Regulation (FPR) 2019/1009) for MagNfix™, its first biological solution, which is a proprietary soybean inoculant seed coating that is designed to support higher soybean yield and protein content. In addition, Protealis has secured the registration of five new soybean varieties across four European countries. This includes the introduction of two new maturity group (MG) 000 soybean varieties in Poland, the registration of its first maturity group 0000 ultra-early soybean variety in France, and a new soy variety registration for Belgium. In Germany, Protealis received registration for its second 00 MG soybean variety suited for the regions in southern Germany...
press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be